{"id":"NCT00732875","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)","officialTitle":"A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2008-08-12","resultsPosted":"2009-07-21","lastUpdate":"2017-04-13"},"enrollment":92,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"BIOLOGICAL","name":"Infliximab + methotrexate (MTX)","otherNames":["Remicade","SCH 215596"]}],"arms":[{"label":"Open Label Infliximab + Methotrexate","type":"EXPERIMENTAL"}],"summary":"This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.","primaryOutcome":{"measure":"Number of Subjects Experiencing Any Adverse Event","timeFrame":"throughout entire study (61 +/- 28.9 weeks on average)","effectByArm":[{"arm":"Open Label Infliximab + Methotrexate","deltaMin":76,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24339699"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":92},"commonTop":["upper respiratory tract infection","pruritus","urticaria","nausea","headache"]}}